{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:55:08Z","timestamp":1792799708153,"version":"4.5.0"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41582-022-00618-9","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T13:02:58Z","timestamp":1645102978000},"page":"203-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-2075","authenticated-orcid":false,"given":"Jee-Young","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-7009","authenticated-orcid":false,"given":"Antonio","family":"Martin-Bastida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6943","authenticated-orcid":false,"given":"Ane","family":"Murueta-Goyena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-2840","authenticated-orcid":false,"given":"I\u00f1igo","family":"Gabilondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-5710","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beomseok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"618_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici, K. & Braak, H. Review: Sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol. Appl. Neurobiol. 42, 33\u201350 (2016).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"618_CR2","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"618_CR3","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.3233\/JPD-179001","volume":"7","author":"H Braak","year":"2017","unstructured":"Braak, H. & Del Tredici, K. Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff. J. Parkinsons Dis. 7, S71\u2013S85 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1474-4422(13)70047-4","volume":"12","author":"D Berg","year":"2013","unstructured":"Berg, D. et al. Changing the research criteria for the diagnosis of Parkinson\u2019s disease: obstacles and opportunities. Lancet Neurol. 12, 514\u2013524 (2013).","journal-title":"Lancet Neurol."},{"key":"618_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","volume":"9","author":"A London","year":"2013","unstructured":"London, A., Benhar, I. & Schwartz, M. The retina as a window to the brain\u2013from eye research to CNS disorders. Nat. Rev. Neurol. 9, 44\u201353 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"618_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/jop.2016.0180","volume":"34","author":"L De Groef","year":"2018","unstructured":"De Groef, L. & Cordeiro, M. F. Is the eye an extension of the brain in central nervous system disease? J. Ocul. Pharmacol. Ther. 34, 129\u2013133 (2018).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"618_CR7","first-page":"2473","volume":"31","author":"C Harnois","year":"1990","unstructured":"Harnois, C. & Di Paolo, T. Decreased dopamine in the retinas of patients with Parkinson\u2019s disease. Invest. Ophthalmol. Vis. Sci. 31, 2473\u20132475 (1990).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1023\/B:DOOP.0000019487.88486.0a","volume":"108","author":"P Witkovsky","year":"2004","unstructured":"Witkovsky, P. Dopamine and retinal function. Doc. Ophthalmol. 108, 17\u201340 (2004).","journal-title":"Doc. Ophthalmol."},{"key":"618_CR9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/brain\/110.6.1675","volume":"110","author":"I Bodis-Wollner","year":"1987","unstructured":"Bodis-Wollner, I. et al. Visual dysfunction in Parkinson\u2019s disease. Loss in spatiotemporal contrast sensitivity. Brain 110, 1675\u20131698 (1987).","journal-title":"Brain"},{"key":"618_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archneur.1993.00540070041012","volume":"50","author":"JT Hutton","year":"1993","unstructured":"Hutton, J. T., Morris, J. L. & Elias, J. W. Levodopa improves spatial contrast sensitivity in Parkinson\u2019s disease. Arch. Neurol. 50, 721\u2013724 (1993).","journal-title":"Arch. Neurol."},{"key":"618_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.27914","volume":"35","author":"JY Lee","year":"2020","unstructured":"Lee, J. Y. et al. Retina thickness as a marker of neurodegeneration in prodromal lewy body disease. Mov. Disord. 35, 349\u2013354 (2020).","journal-title":"Mov. Disord."},{"key":"618_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ana.25897","volume":"88","author":"I Ortu\u00f1o-Lizar\u00e1n","year":"2020","unstructured":"Ortu\u00f1o-Lizar\u00e1n, I. et al. Dopaminergic retinal cell loss and visual dysfunction in Parkinson disease. Ann. Neurol. 88, 893\u2013906 (2020).","journal-title":"Ann. Neurol."},{"key":"618_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/mds.27392","volume":"33","author":"I Ortu\u00f1o-Lizar\u00e1n","year":"2018","unstructured":"Ortu\u00f1o-Lizar\u00e1n, I. et al. Phosphorylated \u03b1-synuclein in the retina is a biomarker of Parkinson\u2019s disease pathology severity. Mov. Disord. 33, 1315\u20131324 (2018).","journal-title":"Mov. Disord."},{"key":"618_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12862-x","volume":"7","author":"S Baksi","year":"2017","unstructured":"Baksi, S. & Singh, N. \u03b1-Synuclein impairs ferritinophagy in the retinal pigment epithelium: implications for retinal iron dyshomeostasis in Parkinson\u2019s disease. Sci. Rep. 7, 12843 (2017).","journal-title":"Sci. Rep."},{"key":"618_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.09.013","volume":"121","author":"N Mammadova","year":"2019","unstructured":"Mammadova, N. et al. Accelerated accumulation of retinal \u03b1-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson\u2019s disease. Neurobiol. Dis. 121, 1\u201316 (2019).","journal-title":"Neurobiol. Dis."},{"key":"618_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/mds.27728","volume":"34","author":"A Murueta-Goyena","year":"2019","unstructured":"Murueta-Goyena, A. et al. Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases. Mov. Disord. 34, 1315\u20131324 (2019).","journal-title":"Mov. Disord."},{"key":"618_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.25543","volume":"29","author":"JY Lee","year":"2014","unstructured":"Lee, J. Y. et al. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson\u2019s disease. Mov. Disord. 29, 61\u201367 (2014).","journal-title":"Mov. Disord."},{"key":"618_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ana.25944","volume":"89","author":"A Murueta-Goyena","year":"2021","unstructured":"Murueta-Goyena, A. et al. Retinal thickness predicts the risk of cognitive decline in Parkinson disease. Ann. Neurol. 89, 165\u2013176 (2021).","journal-title":"Ann. Neurol."},{"key":"618_CR19","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1212\/WNL.0000000000006157","volume":"91","author":"J Ahn","year":"2018","unstructured":"Ahn, J. et al. Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology 91, e1003\u2013e1012 (2018).","journal-title":"Neurology"},{"key":"618_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00702-019-02097-7","volume":"126","author":"JY Lee","year":"2019","unstructured":"Lee, J. Y. et al. Macular ganglion-cell-complex layer thinning and optic nerve integrity in drug-naive Parkinson\u2019s disease. J. Neural Transm. 126, 1695\u20131699 (2019).","journal-title":"J. Neural Transm."},{"key":"618_CR21","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"618_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/BF02147990","volume":"20","author":"A Dahlstrom","year":"1964","unstructured":"Dahlstrom, A. & Fuxe, K. Localization of monoamines in the lower brain stem. Experientia 20, 398\u2013399 (1964).","journal-title":"Experientia"},{"key":"618_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-171184","volume":"8","author":"LJ Ma","year":"2018","unstructured":"Ma, L. J. et al. Progressive changes in the retinal structure of patients with Parkinson\u2019s disease. J. Parkinsons Dis. 8, 85\u201392 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain 122, 1437\u20131448 (1999).","journal-title":"Brain"},{"key":"618_CR25","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/mds.26043","volume":"29","author":"S Lehericy","year":"2014","unstructured":"Lehericy, S., Bardinet, E., Poupon, C., Vidailhet, M. & Francois, C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson\u2019s disease. Mov. Disord. 29, 1574\u20131581 (2014).","journal-title":"Mov. Disord."},{"key":"618_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2012","unstructured":"Jellinger, K. A. Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Mov. Disord. 27, 8\u201330 (2012).","journal-title":"Mov. Disord."},{"key":"618_CR27","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley, J. M. & Lees, A. J. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114, 2283\u20132301 (1991).","journal-title":"Brain"},{"key":"618_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08858-y","volume":"10","author":"I Carballo-Carbajal","year":"2019","unstructured":"Carballo-Carbajal, I. et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson\u2019s disease pathogenesis. Nat. Commun. 10, 973 (2019).","journal-title":"Nat. Commun."},{"key":"618_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jnen\/63.4.329","volume":"63","author":"TG Beach","year":"2004","unstructured":"Beach, T. G. et al. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J. Neuropathol. Exp. Neurol. 63, 329\u2013337 (2004).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"618_CR30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","volume":"62","author":"E Kuusisto","year":"2003","unstructured":"Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of \u03b1-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241\u20131253 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"618_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.nicl.2017.07.011","volume":"16","author":"C Atkinson-Clement","year":"2017","unstructured":"Atkinson-Clement, C., Pinto, S., Eusebio, A. & Coulon, O. Diffusion tensor imaging in Parkinson\u2019s disease: review and meta-analysis. Neuroimage Clin. 16, 98\u2013110 (2017).","journal-title":"Neuroimage Clin."},{"key":"618_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.26606","volume":"31","author":"C Loane","year":"2016","unstructured":"Loane, C. et al. Aberrant nigral diffusion in Parkinson\u2019s disease: a longitudinal diffusion tensor imaging study. Mov. Disord. 31, 1020\u20131026 (2016).","journal-title":"Mov. Disord."},{"key":"618_CR33","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1212\/01.wnl.0000340982.01727.6e","volume":"72","author":"DE Vaillancourt","year":"2009","unstructured":"Vaillancourt, D. E. et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72, 1378\u20131384 (2009).","journal-title":"Neurology"},{"key":"618_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mrm.22055","volume":"62","author":"O Pasternak","year":"2009","unstructured":"Pasternak, O., Sochen, N., Gur, Y., Intrator, N. & Assaf, Y. Free water elimination and mapping from diffusion MRI. Magn. Reson. Med. 62, 717\u2013730 (2009).","journal-title":"Magn. Reson. Med."},{"key":"618_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.neurobiolaging.2014.10.029","volume":"36","author":"E Ofori","year":"2015","unstructured":"Ofori, E. et al. Increased free water in the substantia nigra of Parkinson\u2019s disease: a single-site and multi-site study. Neurobiol. Aging 36, 1097\u20131104 (2015).","journal-title":"Neurobiol. Aging"},{"key":"618_CR36","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/brain\/awv136","volume":"138","author":"E Ofori","year":"2015","unstructured":"Ofori, E. et al. Longitudinal changes in free-water within the substantia nigra of Parkinson\u2019s disease. Brain 138, 2322\u20132331 (2015).","journal-title":"Brain"},{"key":"618_CR37","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/awx146","volume":"140","author":"RG Burciu","year":"2017","unstructured":"Burciu, R. G. et al. Progression marker of Parkinson\u2019s disease: a 4-year multi-site imaging study. Brain 140, 2183\u20132192 (2017).","journal-title":"Brain"},{"key":"618_CR38","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/brain\/awab039","volume":"144","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain 144, 1488\u20131497 (2021).","journal-title":"Brain"},{"key":"618_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3174\/ajnr.A5545","volume":"39","author":"T Guttuso Jr.","year":"2018","unstructured":"Guttuso, T. Jr. et al. Substantia nigra free water increases longitudinally in Parkinson disease. Am. J. Neuroradiol. 39, 479\u2013484 (2018).","journal-title":"Am. J. Neuroradiol."},{"key":"618_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.parkreldis.2019.05.033","volume":"65","author":"G Arribarat","year":"2019","unstructured":"Arribarat, G. et al. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson\u2019s disease. Parkinsonism Relat. Disord. 65, 146\u2013152 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/brain\/awv361","volume":"139","author":"PJ Planetta","year":"2016","unstructured":"Planetta, P. J. et al. Free-water imaging in Parkinson\u2019s disease and atypical parkinsonism. Brain 139, 495\u2013508 (2016).","journal-title":"Brain"},{"key":"618_CR42","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/mds.25491","volume":"28","author":"J Prodoehl","year":"2013","unstructured":"Prodoehl, J. et al. Diffusion tensor imaging of Parkinson\u2019s disease, atypical parkinsonism, and essential tremor. Mov. Disord. 28, 1816\u20131822 (2013).","journal-title":"Mov. Disord."},{"key":"618_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2018.02.046","volume":"51","author":"C Andica","year":"2018","unstructured":"Andica, C. et al. Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson\u2019s disease: retrograde degeneration observed by tract-profile analysis. Parkinsonism Relat. Disord. 51, 55\u201360 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR44","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s00330-015-4066-8","volume":"26","author":"K Kamagata","year":"2016","unstructured":"Kamagata, K. et al. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. Eur. Radiol. 26, 2567\u20132577 (2016).","journal-title":"Eur. Radiol."},{"key":"618_CR45","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/hbm.24760","volume":"40","author":"T Mitchell","year":"2019","unstructured":"Mitchell, T. et al. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum. Brain Mapp. 40, 5094\u20135107 (2019).","journal-title":"Hum. Brain Mapp."},{"key":"618_CR46","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1016\/S2589-7500(19)30105-0","volume":"1","author":"DB Archer","year":"2019","unstructured":"Archer, D. B. et al. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit. Health 1, e222\u2013e231 (2019).","journal-title":"Lancet Digit. Health"},{"key":"618_CR47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(87)91361-4","volume":"2","author":"DT Dexter","year":"1987","unstructured":"Dexter, D. T. et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219\u20131220 (1987).","journal-title":"Lancet"},{"key":"618_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1471-4159.1958.tb12607.x","volume":"3","author":"B Hallgren","year":"1958","unstructured":"Hallgren, B. & Sourander, P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3, 41\u201351 (1958).","journal-title":"J. Neurochem."},{"key":"618_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mri.2004.10.001","volume":"23","author":"EM Haacke","year":"2005","unstructured":"Haacke, E. M. et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn. Reson. Imaging 23, 1\u201325 (2005).","journal-title":"Magn. Reson. Imaging"},{"key":"618_CR50","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s10072-017-3099-y","volume":"38","author":"S Pietracupa","year":"2017","unstructured":"Pietracupa, S., Martin-Bastida, A. & Piccini, P. Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review. Neurol. Sci. 38, 2095\u20132101 (2017).","journal-title":"Neurol. Sci."},{"key":"618_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep36669","volume":"6","author":"JY Wang","year":"2016","unstructured":"Wang, J. Y. et al. Meta-analysis of brain iron levels of Parkinson\u2019s disease patients determined by postmortem and MRI measurements. Sci. Rep. 6, 36669 (2016).","journal-title":"Sci. Rep."},{"key":"618_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/mds.27929","volume":"35","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 35, 478\u2013485 (2020).","journal-title":"Mov. Disord."},{"key":"618_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mds.27608","volume":"34","author":"J Langley","year":"2019","unstructured":"Langley, J. et al. Reproducible detection of nigral iron deposition in 2 Parkinson\u2019s disease cohorts. Mov. Disord. 34, 416\u2013419 (2019).","journal-title":"Mov. Disord."},{"key":"618_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mds.26883","volume":"32","author":"J Langley","year":"2017","unstructured":"Langley, J., Huddleston, D. E., Sedlacik, J., Boelmans, K. & Hu, X. P. Parkinson\u2019s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. Mov. Disord. 32, 441\u2013449 (2017).","journal-title":"Mov. Disord."},{"key":"618_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mds.27730","volume":"34","author":"N Bergsland","year":"2019","unstructured":"Bergsland, N. et al. Ventral posterior substantia nigra iron increases over 3 years in Parkinson\u2019s disease. Mov. Disord. 34, 1006\u20131013 (2019).","journal-title":"Mov. Disord."},{"key":"618_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.mri.2015.02.021","volume":"33","author":"JH Barbosa","year":"2015","unstructured":"Barbosa, J. H. et al. Quantifying brain iron deposition in patients with Parkinson\u2019s disease using quantitative susceptibility mapping, R2 and R2. Magn. Reson. Imaging 33, 559\u2013565 (2015).","journal-title":"Magn. Reson. Imaging"},{"key":"618_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/brain\/aww278","volume":"140","author":"J Acosta-Cabronero","year":"2017","unstructured":"Acosta-Cabronero, J. et al. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson\u2019s disease. Brain 140, 118\u2013131 (2017).","journal-title":"Brain"},{"key":"618_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","volume":"91","author":"GEC Thomas","year":"2020","unstructured":"Thomas, G. E. C. et al. Brain iron deposition is linked with cognitive severity in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 91, 418\u2013425 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"618_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057904","volume":"8","author":"M Ulla","year":"2013","unstructured":"Ulla, M. et al. Is R2* a new MRI biomarker for the progression of Parkinson\u2019s disease? A longitudinal follow-up. PLoS ONE 8, e57904 (2013).","journal-title":"PLoS ONE"},{"key":"618_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.parkreldis.2014.11.017","volume":"21","author":"M Wieler","year":"2015","unstructured":"Wieler, M., Gee, M. & Martin, W. R. Longitudinal midbrain changes in early Parkinson\u2019s disease: iron content estimated from R2*\/MRI. Parkinsonism Relat. Disord. 21, 179\u2013183 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093814","volume":"9","author":"ST Schwarz","year":"2014","unstructured":"Schwarz, S. T. et al. The \u2018swallow tail\u2019 appearance of the healthy nigrosome\u2013a new accurate test of Parkinson\u2019s disease: a case\u2013control and retrospective cross-sectional MRI study at 3T. PLoS ONE 9, e93814 (2014).","journal-title":"PLoS ONE"},{"key":"618_CR62","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.nicl.2018.05.027","volume":"19","author":"ST Schwarz","year":"2018","unstructured":"Schwarz, S. T. et al. Parkinson\u2019s disease related signal change in the nigrosomes 1\u20135 and the substantia nigra using T2* weighted 7T MRI. Neuroimage Clin. 19, 683\u2013689 (2018).","journal-title":"Neuroimage Clin."},{"key":"618_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.01.023","volume":"26","author":"JM Kim","year":"2016","unstructured":"Kim, J. M. et al. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat. Disord. 26, 47\u201354 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1148\/radiol.2017162486","volume":"287","author":"YJ Bae","year":"2018","unstructured":"Bae, Y. J. et al. Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: comparison with (123)I-FP-CIT SPECT. Radiology 287, 285\u2013293 (2018).","journal-title":"Radiology"},{"key":"618_CR65","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ana.24646","volume":"79","author":"R De Marzi","year":"2016","unstructured":"De Marzi, R. et al. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 79, 1026\u20131030 (2016).","journal-title":"Ann. Neurol."},{"key":"618_CR66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2017.08.002","volume":"43","author":"D Frosini","year":"2017","unstructured":"Frosini, D. et al. Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism Relat. Disord. 43, 105\u2013109 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR67","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/mds.26171","volume":"30","author":"E Reiter","year":"2015","unstructured":"Reiter, E. et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov. Disord. 30, 1068\u20131076 (2015).","journal-title":"Mov. Disord."},{"key":"618_CR68","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.26584","volume":"31","author":"YJ Bae","year":"2016","unstructured":"Bae, Y. J. et al. Loss of nigral hyperintensity on 3 Tesla MRI of parkinsonism: comparison with (123)I-FP-CIT SPECT. Mov. Disord. 31, 684\u2013692 (2016).","journal-title":"Mov. Disord."},{"key":"618_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2018.01.008","volume":"386","author":"H An","year":"2018","unstructured":"An, H. et al. Quantifying iron deposition within the substantia nigra of Parkinson\u2019s disease by quantitative susceptibility mapping. J. Neurol. Sci. 386, 46\u201352 (2018).","journal-title":"J. Neurol. Sci."},{"key":"618_CR70","doi-asserted-by":"publisher","first-page":"109398","DOI":"10.1016\/j.ejrad.2020.109398","volume":"134","author":"YJ Bae","year":"2021","unstructured":"Bae, Y. J. et al. Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity. Eur. J. Radiol. 134, 109398 (2021).","journal-title":"Eur. J. Radiol."},{"key":"618_CR71","doi-asserted-by":"publisher","first-page":"102103","DOI":"10.1016\/j.nicl.2019.102103","volume":"25","author":"Z Cheng","year":"2020","unstructured":"Cheng, Z. et al. Imaging the nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: an application to Parkinson\u2019s disease. Neuroimage Clin. 25, 102103 (2020).","journal-title":"Neuroimage Clin."},{"key":"618_CR72","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jmri.25553","volume":"46","author":"Y Nam","year":"2017","unstructured":"Nam, Y., Gho, S. M., Kim, D. H., Kim, E. Y. & Lee, J. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI). J. Magn. Reson. Imaging 46, 528\u2013536 (2017).","journal-title":"J. Magn. Reson. Imaging"},{"key":"618_CR73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3988\/jcn.2018.14.1.90","volume":"14","author":"EY Kim","year":"2018","unstructured":"Kim, E. Y. et al. Diagnosis of early-stage idiopathic Parkinson\u2019s disease using high-resolution quantitative susceptibility mapping combined with histogram analysis in the substantia nigra at 3 T. J. Clin. Neurol. 14, 90\u201397 (2018).","journal-title":"J. Clin. Neurol."},{"key":"618_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/acn3.50962","volume":"7","author":"TR Barber","year":"2020","unstructured":"Barber, T. R. et al. Nigrosome 1 imaging in REM sleep behavior disorder and its association with dopaminergic decline. Ann. Clin. Transl. Neurol. 7, 26\u201335 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"618_CR75","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/mds.28204","volume":"35","author":"S Reimao","year":"2020","unstructured":"Reimao, S., Guerreiro, C., Seppi, K., Ferreira, J. J. & Poewe, W. A standardized MR imaging protocol for parkinsonism. Mov. Disord. 35, 1745\u20131750 (2020).","journal-title":"Mov. Disord."},{"key":"618_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pneurobio.2005.02.001","volume":"75","author":"H Fedorow","year":"2005","unstructured":"Fedorow, H. et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson\u2019s disease. Prog. Neurobiol. 75, 109\u2013124 (2005).","journal-title":"Prog. Neurobiol."},{"key":"618_CR77","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.1073\/pnas.97.22.11869","volume":"97","author":"D Sulzer","year":"2000","unstructured":"Sulzer, D. et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl Acad. Sci. USA 97, 11869\u201311874 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"618_CR78","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2008.05541.x","volume":"106","author":"L Zecca","year":"2008","unstructured":"Zecca, L. et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson\u2019s disease. J. Neurochem. 106, 1866\u20131875 (2008).","journal-title":"J. Neurochem."},{"key":"618_CR79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12640-009-9140-z","volume":"19","author":"W Zhang","year":"2011","unstructured":"Zhang, W. et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson\u2019s disease. Neurotox. Res. 19, 63\u201372 (2011).","journal-title":"Neurotox. Res."},{"key":"618_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-018-0047-3","volume":"4","author":"D Sulzer","year":"2018","unstructured":"Sulzer, D. et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson\u2019s disease. npj Parkinson\u2019s Dis. 4, 11 (2018).","journal-title":"npj Parkinson\u2019s Dis"},{"key":"618_CR81","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.mri.2014.07.003","volume":"32","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn. Reson. Imaging 32, 1301\u20131306 (2014).","journal-title":"Magn. Reson. Imaging"},{"key":"618_CR82","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/mds.23722","volume":"26","author":"ST Schwarz","year":"2011","unstructured":"Schwarz, S. T. et al. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson\u2019s disease. Mov. Disord. 26, 1633\u20131638 (2011).","journal-title":"Mov. Disord."},{"key":"618_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2013.02.012","volume":"541","author":"C Ohtsuka","year":"2013","unstructured":"Ohtsuka, C. et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson\u2019s disease using neuromelanin-sensitive MR imaging. Neurosci. Lett. 541, 93\u201398 (2013).","journal-title":"Neurosci. Lett."},{"key":"618_CR84","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3233\/JPD-171135","volume":"7","author":"M Fabbri","year":"2017","unstructured":"Fabbri, M. et al. Substantia nigra neuromelanin as an imaging biomarker of disease progression in Parkinson\u2019s disease. J. Parkinsons Dis. 7, 491\u2013501 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR85","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ene.12613","volume":"22","author":"S Reimao","year":"2015","unstructured":"Reimao, S. et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson\u2019s disease patients. Eur. J. Neurol. 22, 540\u2013546 (2015).","journal-title":"Eur. J. Neurol."},{"key":"618_CR86","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/ene.13628","volume":"25","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson\u2019s disease and its phenotypes. Eur. J. Neurol. 25, 949-e73 (2018).","journal-title":"Eur. J. Neurol."},{"key":"618_CR87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000350291","volume":"70","author":"K Matsuura","year":"2013","unstructured":"Matsuura, K. et al. Neuromelanin magnetic resonance imaging in Parkinson\u2019s disease and multiple system atrophy. Eur. Neurol. 70, 70\u201377 (2013).","journal-title":"Eur. Neurol."},{"key":"618_CR88","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","volume":"20","author":"C Ohtsuka","year":"2014","unstructured":"Ohtsuka, C. et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat. Disord. 20, 755\u2013760 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR89","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1148\/radiol.2016160662","volume":"283","author":"ST Schwarz","year":"2017","unstructured":"Schwarz, S. T., Xing, Y., Tomar, P., Bajaj, N. & Auer, D. P. In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283, 789\u2013798 (2017).","journal-title":"Radiology"},{"key":"618_CR90","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/brain\/awaa216","volume":"143","author":"E Biondetti","year":"2020","unstructured":"Biondetti, E. et al. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson\u2019s disease. Brain 143, 2757\u20132770 (2020).","journal-title":"Brain"},{"key":"618_CR91","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/mds.28531","volume":"36","author":"R Gaurav","year":"2021","unstructured":"Gaurav, R. et al. Longitudinal changes in neuromelanin MRI signal in Parkinson\u2019s disease: a progression marker. Mov. Disord. 36, 1592\u20131602 (2021).","journal-title":"Mov. Disord."},{"key":"618_CR92","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neulet.2016.09.011","volume":"633","author":"K Matsuura","year":"2016","unstructured":"Matsuura, K. et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson\u2019s disease. Neurosci. Lett. 633, 112\u2013117 (2016).","journal-title":"Neurosci. Lett."},{"key":"618_CR93","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/brain\/awt152","volume":"136","author":"D Garcia-Lorenzo","year":"2013","unstructured":"Garcia-Lorenzo, D. et al. The coeruleus\/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson\u2019s disease. Brain 136, 2120\u20132129 (2013).","journal-title":"Brain"},{"key":"618_CR94","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/brain\/aww006","volume":"139","author":"M Ehrminger","year":"2016","unstructured":"Ehrminger, M. et al. The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139, 1180\u20131188 (2016).","journal-title":"Brain"},{"key":"618_CR95","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618\u2013628 (2018).","journal-title":"Lancet Neurol."},{"key":"618_CR96","doi-asserted-by":"publisher","first-page":"zsx149","DOI":"10.1093\/sleep\/zsx149","volume":"40","author":"N Pyatigorskaya","year":"2017","unstructured":"Pyatigorskaya, N. et al. Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep 40, zsx149 (2017).","journal-title":"Sleep"},{"key":"618_CR97","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1002\/hbm.23192","volume":"37","author":"J Langley","year":"2016","unstructured":"Langley, J. et al. Diffusion tensor imaging of the substantia nigra in Parkinson\u2019s disease revisited. Hum. Brain Mapp. 37, 2547\u20132556 (2016).","journal-title":"Hum. Brain Mapp."},{"key":"618_CR98","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/hbm.24878","volume":"41","author":"A Safai","year":"2020","unstructured":"Safai, A. et al. Microstructural abnormalities of substantia nigra in Parkinson\u2019s disease: a neuromelanin sensitive MRI atlas based study. Hum. Brain Mapp. 41, 1323\u20131333 (2020).","journal-title":"Hum. Brain Mapp."},{"key":"618_CR99","doi-asserted-by":"publisher","first-page":"117810","DOI":"10.1016\/j.neuroimage.2021.117810","volume":"230","author":"N He","year":"2021","unstructured":"He, N. et al. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson\u2019s disease. Neuroimage 230, 117810 (2021).","journal-title":"Neuroimage"},{"key":"618_CR100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1971400919853787","volume":"32","author":"MS Perez Akly","year":"2019","unstructured":"Perez Akly, M. S. et al. Accuracy of nigrosome-1 detection to discriminate patients with Parkinson\u2019s disease and essential tremor. Neuroradiol. J. 32, 395\u2013400 (2019).","journal-title":"Neuroradiol. J."},{"key":"618_CR101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.007","volume":"58","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Neuromelanin-sensitive MRI of the substantia nigra: an imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson\u2019s disease. Parkinsonism Relat. Disord. 58, 3\u20138 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR102","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fneur.2019.00100","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L. et al. Combined visualization of nigrosome-1 and neuromelanin in the substantia nigra using 3T MRI for the differential diagnosis of essential tremor and de novo Parkinson\u2019s disease. Front. Neurol. 10, 100 (2019).","journal-title":"Front. Neurol."},{"key":"618_CR103","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/brain\/awr233","volume":"134","author":"R Nandhagopal","year":"2011","unstructured":"Nandhagopal, R. et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson\u2019s disease. Brain 134, 3290\u20133298 (2011).","journal-title":"Brain"},{"key":"618_CR104","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ana.22284","volume":"69","author":"R de la Fuente-Fernandez","year":"2011","unstructured":"de la Fuente-Fernandez, R. et al. Age-specific progression of nigrostriatal dysfunction in Parkinson\u2019s disease. Ann. Neurol. 69, 803\u2013810 (2011).","journal-title":"Ann. Neurol."},{"key":"618_CR105","doi-asserted-by":"publisher","first-page":"e3081","DOI":"10.1212\/WNL.0000000000010942","volume":"95","author":"JH Shin","year":"2020","unstructured":"Shin, J. H. et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology 95, e3081\u2013e3092 (2020).","journal-title":"Neurology"},{"key":"618_CR106","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(11)70152-1","volume":"10","author":"A Iranzo","year":"2011","unstructured":"Iranzo, A. et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10, 797\u2013805 (2011).","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"618_CR107","first-page":"628","volume":"59","author":"J Seibyl","year":"2018","unstructured":"Seibyl, J. & Cheng, D. Four year longitudinal assessment of DAT imaging biomarkers in a progressing Parkinson disease cohort: analysis strategies and implications for treatment trial design [abstract]. J. Nucl. Med. 59 (Suppl. 1), 628 (2018).","journal-title":"J. Nucl. Med."},{"key":"618_CR108","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25026","volume":"82","author":"A Iranzo","year":"2017","unstructured":"Iranzo, A. et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 82, 419\u2013428 (2017).","journal-title":"Ann. Neurol."},{"key":"618_CR109","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings, D. et al. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 74, 933\u2013940 (2017).","journal-title":"JAMA Neurol."},{"key":"618_CR110","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JPD-161011","volume":"7","author":"N Lenfeldt","year":"2017","unstructured":"Lenfeldt, N., Eriksson, J., Astrom, B., Forsgren, L. & Mo, S. J. Fractional anisotropy and mean diffusion as measures of dopaminergic function in Parkinson\u2019s disease: challenging results. J. Parkinsons Dis. 7, 129\u2013142 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR111","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnagi.2016.00196","volume":"8","author":"IU Isaias","year":"2016","unstructured":"Isaias, I. U. et al. Neuromelanin imaging and dopaminergic loss in Parkinson\u2019s disease. Front. Aging Neurosci. 8, 196 (2016).","journal-title":"Front. Aging Neurosci."},{"key":"618_CR112","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0284185117722812","volume":"59","author":"K Kuya","year":"2018","unstructured":"Kuya, K. et al. Evaluation of Parkinson\u2019s disease by neuromelanin-sensitive magnetic resonance imaging and (123)I-FP-CIT SPECT. Acta Radiol. 59, 593\u2013598 (2018).","journal-title":"Acta Radiol."},{"key":"618_CR113","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/brain\/awz120","volume":"142","author":"A Martin-Bastida","year":"2019","unstructured":"Martin-Bastida, A. et al. Relationship between neuromelanin and dopamine terminals within the Parkinson\u2019s nigrostriatal system. Brain 142, 2023\u20132036 (2019).","journal-title":"Brain"},{"key":"618_CR114","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari, L. et al. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 88, 1461\u20131467 (2017).","journal-title":"Neurology"},{"key":"618_CR115","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.23798","volume":"73","author":"M Karimi","year":"2013","unstructured":"Karimi, M. et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann. Neurol. 73, 390\u2013396 (2013).","journal-title":"Ann. Neurol."},{"key":"618_CR116","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain 136, 2419\u20132431 (2013).","journal-title":"Brain"},{"key":"618_CR117","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1093\/brain\/awab191","volume":"144","author":"E Biondetti","year":"2021","unstructured":"Biondetti, E. et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson\u2019s disease. Brain 144, 3114\u20133125 (2021).","journal-title":"Brain"},{"key":"618_CR118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0006-8993(90)91056-M","volume":"527","author":"WG Tatton","year":"1990","unstructured":"Tatton, W. G., Kwan, M. M., Verrier, M. C., Seniuk, N. A. & Theriault, E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 527, 21\u201331 (1990).","journal-title":"Brain Res."},{"key":"618_CR119","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s11064-012-0706-4","volume":"37","author":"T Meng","year":"2012","unstructured":"Meng, T., Zheng, Z. H., Liu, T. T. & Lin, L. Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat. Neurochem. Res. 37, 1050\u20131056 (2012).","journal-title":"Neurochem. Res."},{"key":"618_CR120","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nbd.2011.06.009","volume":"44","author":"J Esteve-Rudd","year":"2011","unstructured":"Esteve-Rudd, J. et al. Rotenone induces degeneration of photoreceptors and impairs the dopaminergic system in the rat retina. Neurobiol. Dis. 44, 102\u2013115 (2011).","journal-title":"Neurobiol. Dis."},{"key":"618_CR121","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/BF01188404","volume":"19","author":"H Kolb","year":"1990","unstructured":"Kolb, H., Cuenca, N., Wang, H. H. & Dekorver, L. The synaptic organization of the dopaminergic amacrine cell in the cat retina. J. Neurocytol. 19, 343\u2013366 (1990).","journal-title":"J. Neurocytol."},{"key":"618_CR122","unstructured":"Popova, E. The role of dopamine in retinal function. Webvision https:\/\/webvision.med.utah.edu\/book\/part-iv-neurotransmitters-in-the-retina-2\/the-role-of-dopamine-in-retinal-function-by-elka-popova\/ (2021)."},{"key":"618_CR123","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/brain\/101.4.661","volume":"101","author":"I Bodis-Wollner","year":"1978","unstructured":"Bodis-Wollner, I. & Yahr, M. D. Measurements of visual evoked potentials in Parkinson\u2019s disease. Brain 101, 661\u2013671 (1978).","journal-title":"Brain"},{"key":"618_CR124","first-page":"7","volume":"5","author":"BS Jeon","year":"1987","unstructured":"Jeon, B. S., Lee, K. W., Lee, S. B. & Myung, H. J. Flash ERG findings in Parkinson\u2019s disease. J. Korean Neurol. Assoc. 5, 7 (1987).","journal-title":"J. Korean Neurol. Assoc."},{"key":"618_CR125","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1167\/iovs.13-13062","volume":"55","author":"E Garcia-Martin","year":"2014","unstructured":"Garcia-Martin, E. et al. Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity. Invest. Ophthalmol. Vis. Sci. 55, 696\u2013705 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1388-2457(99)00223-0","volume":"111","author":"T Langheinrich","year":"2000","unstructured":"Langheinrich, T. et al. Visual contrast response functions in Parkinson\u2019s disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Clin. Neurophysiol. 111, 66\u201374 (2000).","journal-title":"Clin. Neurophysiol."},{"key":"618_CR127","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5301\/EJO.2010.1318","volume":"21","author":"MM Moschos","year":"2011","unstructured":"Moschos, M. M. et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur. J. Ophthalmol. 21, 24\u201329 (2011).","journal-title":"Eur. J. Ophthalmol."},{"key":"618_CR128","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0013-4694(92)90051-I","volume":"82","author":"A Peppe","year":"1992","unstructured":"Peppe, A. et al. Low contrast stimuli enhance PERG sensitivity to the visual dysfunction in Parkinson\u2019s disease. Electroencephalogr. Clin. Neurophysiol. 82, 453\u2013457 (1992).","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"618_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0168-5597(95)00169-7","volume":"100","author":"M Tagliati","year":"1996","unstructured":"Tagliati, M., Bodis-Wollner, I. & Yahr, M. D. The pattern electroretinogram in Parkinson\u2019s disease reveals lack of retinal spatial tuning. Electroencephalogr. Clin. Neurophysiol. 100, 1\u201311 (1996).","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"618_CR130","first-page":"115","volume":"4","author":"P Stanzione","year":"1989","unstructured":"Stanzione, P. et al. Pattern visual evoked potentials and electroretinogram abnormalities in Parkinson\u2019s disease: effects of L-dopa therapy. Clin. Vis. Sci. 4, 115\u2013127 (1989).","journal-title":"Clin. Vis. Sci."},{"key":"618_CR131","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/S0042-6989(98)00028-5","volume":"38","author":"I Bodis-Wollner","year":"1998","unstructured":"Bodis-Wollner, I. & Tzelepi, A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vis. Res. 38, 1479\u20131487 (1998).","journal-title":"Vis. Res."},{"key":"618_CR132","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/jnnp.52.3.341","volume":"52","author":"C Bulens","year":"1989","unstructured":"Bulens, C., Meerwaldt, J. D., van der Wildt, G. J. & Keemink, C. J. Visual contrast sensitivity in drug-induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 52, 341\u2013345 (1989).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"618_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2012.07.012","volume":"19","author":"I Bodis-Wollner","year":"2013","unstructured":"Bodis-Wollner, I. Foveal vision is impaired in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 1\u201314 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR134","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archneur.59.8.1249","volume":"59","author":"NJ Diederich","year":"2002","unstructured":"Diederich, N. J., Raman, R., Leurgans, S. & Goetz, C. G. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch. Neurol. 59, 1249\u20131252 (2002).","journal-title":"Arch. Neurol."},{"key":"618_CR135","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/brain\/awh581","volume":"128","author":"MF Silva","year":"2005","unstructured":"Silva, M. F. et al. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson\u2019s disease. Brain 128, 2260\u20132271 (2005).","journal-title":"Brain"},{"key":"618_CR136","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10792-018-0934-y","volume":"39","author":"S Hasanov","year":"2019","unstructured":"Hasanov, S. et al. Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson\u2019s disease. Int. Ophthalmol. 39, 1255\u20131262 (2019).","journal-title":"Int. Ophthalmol."},{"key":"618_CR137","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0891988719845501","volume":"32","author":"E Matar","year":"2019","unstructured":"Matar, E., Phillips, J. R., Martens, K. A. E., Halliday, G. M. & Lewis, S. J. G. Impaired color discrimination\u2013a specific marker of hallucinations in Lewy body disorders. J. Geriatr. Psychiatry Neurol. 32, 257\u2013264 (2019).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"618_CR138","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/mds.25272","volume":"27","author":"JA Bertrand","year":"2012","unstructured":"Bertrand, J. A. et al. Color discrimination deficits in Parkinson\u2019s disease are related to cognitive impairment and white-matter alterations. Mov. Disord. 27, 1781\u20131788 (2012).","journal-title":"Mov. Disord."},{"key":"618_CR139","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/mds.23272","volume":"25","author":"L Kertelge","year":"2010","unstructured":"Kertelge, L. et al. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson\u2019s disease. Mov. Disord. 25, 2665\u20132669 (2010).","journal-title":"Mov. Disord."},{"key":"618_CR140","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1468-1331.2010.03206.x","volume":"18","author":"YS Oh","year":"2011","unstructured":"Oh, Y. S. et al. Color vision in Parkinson\u2019s disease and essential tremor. Eur. J. Neurol. 18, 577\u2013583 (2011).","journal-title":"Eur. J. Neurol."},{"key":"618_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009658","volume":"6","author":"V Polo","year":"2016","unstructured":"Polo, V. et al. Visual dysfunction and its correlation with retinal changes in patients with Parkinson\u2019s disease: an observational cross-sectional study. BMJ Open 6, e009658 (2016).","journal-title":"BMJ Open"},{"key":"618_CR142","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.wnp.0000216127.53517.4d","volume":"23","author":"F Sartucci","year":"2006","unstructured":"Sartucci, F. & Porciatti, V. Visual-evoked potentials to onset of chromatic red-green and blue-yellow gratings in Parkinson\u2019s disease never treated with L-dopa. J. Clin. Neurophysiol. 23, 431\u2013435 (2006).","journal-title":"J. Clin. Neurophysiol."},{"key":"618_CR143","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10072-014-1930-2","volume":"36","author":"I Stenc Bradvica","year":"2015","unstructured":"Stenc Bradvica, I., Bradvica, M., Matic, S. & Reisz-Majic, P. Visual dysfunction in patients with Parkinson\u2019s disease and essential tremor. Neurol. Sci. 36, 257\u2013262 (2015).","journal-title":"Neurol. Sci."},{"key":"618_CR144","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000117133","volume":"35","author":"T Buttner","year":"1995","unstructured":"Buttner, T., Kuhn, W. & Przuntek, H. Alterations in chromatic contour perception in de novo parkinsonian patients. Eur. Neurol. 35, 226\u2013229 (1995).","journal-title":"Eur. Neurol."},{"key":"618_CR145","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","volume":"72","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad, S. M. et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 72, 863\u2013873 (2015).","journal-title":"JAMA Neurol."},{"key":"618_CR146","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/118.3.771","volume":"118","author":"BA Haug","year":"1995","unstructured":"Haug, B. A., Kolle, R. U., Trenkwalder, C., Oertel, W. H. & Paulus, W. Predominant affection of the blue cone pathway in Parkinson\u2019s disease. Brain 118, 771\u2013778 (1995).","journal-title":"Brain"},{"key":"618_CR147","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s004150050263","volume":"245","author":"T Muller","year":"1998","unstructured":"Muller, T. et al. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson\u2019s disease. J. Neurol. 245, 659\u2013664 (1998).","journal-title":"J. Neurol."},{"key":"618_CR148","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1046\/j.1468-1331.1999.660711.x","volume":"6","author":"T Muller","year":"1999","unstructured":"Muller, T., Kuhn, W., Buttner, T. & Przuntek, H. Colour vision abnormalities and movement time in Parkinson\u2019s disease. Eur. J. Neurol. 6, 711\u2013715 (1999).","journal-title":"Eur. J. Neurol."},{"key":"618_CR149","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0022-510X(99)00204-X","volume":"172","author":"V Pieri","year":"2000","unstructured":"Pieri, V., Diederich, N. J., Raman, R. & Goetz, C. G. Decreased color discrimination and contrast sensitivity in Parkinson\u2019s disease. J. Neurol. Sci. 172, 7\u201311 (2000).","journal-title":"J. Neurol. Sci."},{"key":"618_CR150","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/mds.22099","volume":"23","author":"RB Postuma","year":"2008","unstructured":"Postuma, R. B., Gagnon, J. F., Vendette, M., Charland, K. & Montplaisir, J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov. Disord. 23, 1665\u20131672 (2008).","journal-title":"Mov. Disord."},{"key":"618_CR151","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1212\/WNL.42.4.887","volume":"42","author":"MJ Price","year":"1992","unstructured":"Price, M. J., Feldman, R. G., Adelberg, D. & Kayne, H. Abnormalities in color vision and contrast sensitivity in Parkinson\u2019s disease. Neurology 42, 887\u2013890 (1992).","journal-title":"Neurology"},{"key":"618_CR152","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/S0042-6989(97)00402-1","volume":"38","author":"BC Regan","year":"1998","unstructured":"Regan, B. C., Freudenthaler, N., Kolle, R., Mollon, J. D. & Paulus, W. Colour discrimination thresholds in Parkinson\u2019s disease: results obtained with a rapid computer-controlled colour vision test. Vis. Res. 38, 3427\u20133431 (1998).","journal-title":"Vis. Res."},{"key":"618_CR153","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1167\/iovs.16-20460","volume":"58","author":"M Satue","year":"2017","unstructured":"Satue, M. et al. Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson\u2019s disease. Invest. Ophthalmol. Vis. Sci. 58, 1151\u20131157 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR154","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0168-5597(94)90057-4","volume":"92","author":"L Barbato","year":"1994","unstructured":"Barbato, L., Rinalduzzi, S., Laurenti, M., Ruggieri, S. & Accornero, N. Color VEPs in Parkinson\u2019s disease. Electroencephalogr. Clin. Neurophysiol. 92, 169\u2013172 (1994).","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"618_CR155","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1016\/S0042-6989(97)00398-2","volume":"38","author":"J Birch","year":"1998","unstructured":"Birch, J., Kolle, R. U., Kunkel, M., Paulus, W. & Upadhyay, P. Acquired colour deficiency in patients with Parkinson\u2019s disease. Vis. Res. 38, 3421\u20133426 (1998).","journal-title":"Vis. Res."},{"key":"618_CR156","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/mds.870070308","volume":"7","author":"RD Jones","year":"1992","unstructured":"Jones, R. D., Donaldson, I. M. & Timmings, P. L. Impairment of high-contrast visual acuity in Parkinson\u2019s disease. Mov. Disord. 7, 232\u2013238 (1992).","journal-title":"Mov. Disord."},{"key":"618_CR157","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JPD-140470","volume":"5","author":"TP Lin","year":"2015","unstructured":"Lin, T. P. et al. Abnormal visual contrast acuity in Parkinson\u2019s disease. J. Parkinsons Dis. 5, 125\u2013130 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR158","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mdc3.12821","volume":"6","author":"HV Gupta","year":"2019","unstructured":"Gupta, H. V. et al. Contrast acuity with different colors in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 6, 672\u2013677 (2019).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"618_CR159","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/bjo.68.12.885","volume":"68","author":"D Regan","year":"1984","unstructured":"Regan, D. & Neima, D. Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson\u2019s disease. Br. J. Ophthalmol. 68, 885\u2013889 (1984).","journal-title":"Br. J. Ophthalmol."},{"key":"618_CR160","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/brain\/112.5.1193","volume":"112","author":"O Rascol","year":"1989","unstructured":"Rascol, O. et al. Abnormal ocular movements in Parkinson\u2019s disease. Evidence for involvement of dopaminergic systems. Brain 112, 1193\u20131214 (1989).","journal-title":"Brain"},{"key":"618_CR161","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.neuropsychologia.2011.03.002","volume":"49","author":"Y Terao","year":"2011","unstructured":"Terao, Y. et al. Initiation and inhibitory control of saccades with the progression of Parkinson\u2019s disease\u2013changes in three major drives converging on the superior colliculus. Neuropsychologia 49, 1794\u20131806 (2011).","journal-title":"Neuropsychologia"},{"key":"618_CR162","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10072-009-0180-1","volume":"31","author":"S Marino","year":"2010","unstructured":"Marino, S., Lanzafame, P., Sessa, E., Bramanti, A. & Bramanti, P. The effect of L-Dopa administration on pursuit ocular movements in suspected Parkinson\u2019s disease. Neurol. Sci. 31, 381\u2013385 (2010).","journal-title":"Neurol. Sci."},{"key":"618_CR163","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fnagi.2020.00120","volume":"12","author":"L Stock","year":"2020","unstructured":"Stock, L., Kruger-Zechlin, C., Deeb, Z., Timmermann, L. & Waldthaler, J. Natural reading in Parkinson\u2019s disease with and without mild cognitive impairment. Front. Aging Neurosci. 12, 120 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"618_CR164","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ana.25696","volume":"87","author":"E Moro","year":"2020","unstructured":"Moro, E. et al. Visual dysfunction of the superior colliculus in de novo parkinsonian patients. Ann. Neurol. 87, 533\u2013546 (2020).","journal-title":"Ann. Neurol."},{"key":"618_CR165","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awp068","volume":"132","author":"NK Archibald","year":"2009","unstructured":"Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. The retina in Parkinson\u2019s disease. Brain 132, 1128\u20131145 (2009).","journal-title":"Brain"},{"key":"618_CR166","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.visres.2004.11.006","volume":"45","author":"S Davidsdottir","year":"2005","unstructured":"Davidsdottir, S., Cronin-Golomb, A. & Lee, A. Visual and spatial symptoms in Parkinson\u2019s disease. Vis. Res. 45, 1285\u20131296 (2005).","journal-title":"Vis. Res."},{"key":"618_CR167","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov. Disord. 31, 45\u201352 (2016).","journal-title":"Mov. Disord."},{"key":"618_CR168","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/jnnp.52.11.1228","volume":"52","author":"VA Bradley","year":"1989","unstructured":"Bradley, V. A., Welch, J. L. & Dick, D. J. Visuospatial working memory in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 52, 1228\u20131235 (1989).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"618_CR169","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3233\/JPD-202122","volume":"10","author":"C Fernandez-Baizan","year":"2020","unstructured":"Fernandez-Baizan, C. et al. Patients with Parkinson\u2019s disease show alteration in their visuospatial abilities and in their egocentric and allocentric spatial orientation measured by card placing tests. J. Parkinsons Dis. 10, 1807\u20131816 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"618_CR170","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.06.020","volume":"31","author":"JJ Lee","year":"2016","unstructured":"Lee, J. J. et al. Optic nerve integrity as a visuospatial cognitive predictor in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 31, 41\u201345 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR171","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ana.24182","volume":"75","author":"I Bodis-Wollner","year":"2014","unstructured":"Bodis-Wollner, I., Kozlowski, P. B., Glazman, S. & Miri, S. \u03b1-synuclein in the inner retina in parkinson disease. Ann. Neurol. 75, 964\u2013966 (2014).","journal-title":"Ann. Neurol."},{"key":"618_CR172","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neulet.2014.04.027","volume":"571","author":"TG Beach","year":"2014","unstructured":"Beach, T. G. et al. Phosphorylated \u03b1-synuclein-immunoreactive retinal neuronal elements in Parkinson\u2019s disease subjects. Neurosci. Lett. 571, 34\u201338 (2014).","journal-title":"Neurosci. Lett."},{"key":"618_CR173","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/cne.20761","volume":"493","author":"N Cuenca","year":"2005","unstructured":"Cuenca, N. et al. Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson\u2019s disease. J. Comp. Neurol. 493, 261\u2013273 (2005).","journal-title":"J. Comp. Neurol."},{"key":"618_CR174","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0896-6273(02)01046-2","volume":"36","author":"MR Deans","year":"2002","unstructured":"Deans, M. R., Volgyi, B., Goodenough, D. A., Bloomfield, S. A. & Paul, D. L. Connexin36 is essential for transmission of rod-mediated visual signals in the mammalian retina. Neuron 36, 703\u2013712 (2002).","journal-title":"Neuron"},{"key":"618_CR175","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1212\/WNL.0b013e31821671a5","volume":"76","author":"EE Benarroch","year":"2011","unstructured":"Benarroch, E. E. The melanopsin system: phototransduction, projections, functions, and clinical implications. Neurology 76, 1422\u20131427 (2011).","journal-title":"Neurology"},{"key":"618_CR176","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.tins.2018.03.002","volume":"41","author":"K Fifel","year":"2018","unstructured":"Fifel, K. & Videnovic, A. Light therapy in Parkinson\u2019s disease: towards mechanism-based protocols. Trends Neurosci. 41, 252\u2013254 (2018).","journal-title":"Trends Neurosci."},{"key":"618_CR177","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fnagi.2017.00079","volume":"9","author":"G Esquiva","year":"2017","unstructured":"Esquiva, G., Lax, P., Perez-Santonja, J. J., Garcia-Fernandez, J. M. & Cuenca, N. Loss of melanopsin-expressing ganglion cell subtypes and dendritic degeneration in the aging human retina. Front. Aging Neurosci. 9, 79 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"618_CR178","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-018-0596-z","volume":"6","author":"I Ortu\u00f1o-Lizar\u00e1n","year":"2018","unstructured":"Ortu\u00f1o-Lizar\u00e1n, I. et al. Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson\u2019s disease. Acta Neuropathol. Commun. 6, 90 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"618_CR179","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0074-7696(00)96006-6","volume":"196","author":"J Nguyen-Legros","year":"2000","unstructured":"Nguyen-Legros, J. & Hicks, D. Renewal of photoreceptor outer segments and their phagocytosis by the retinal pigment epithelium. Int. Rev. Cytol. 196, 245\u2013313 (2000).","journal-title":"Int. Rev. Cytol."},{"key":"618_CR180","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1167\/iovs.10-6312","volume":"52","author":"ML Gabriele","year":"2011","unstructured":"Gabriele, M. L. et al. Optical coherence tomography: history, current status, and laboratory work. Invest. Ophthalmol. Vis. Sci. 52, 2425\u20132436 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR181","doi-asserted-by":"publisher","first-page":"OCT1","DOI":"10.1167\/iovs.16-19963","volume":"57","author":"J Fujimoto","year":"2016","unstructured":"Fujimoto, J. & Swanson, E. The development, commercialization, and impact of optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 57, OCT1\u2013OCT13 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR182","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz, A. et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology 86, 2303\u20132309 (2016).","journal-title":"Neurology"},{"key":"618_CR183","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.0000000000012125","volume":"97","author":"A Aytulun","year":"2021","unstructured":"Aytulun, A. et al. APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology 97, 68\u201379 (2021).","journal-title":"Neurology"},{"key":"618_CR184","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10633-007-9091-8","volume":"116","author":"O Altintas","year":"2008","unstructured":"Altintas, O., Iseri, P., Ozkan, B. & Caglar, Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson\u2019s disease. Doc. Ophthalmol. 116, 137\u2013146 (2008).","journal-title":"Doc. Ophthalmol."},{"key":"618_CR185","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.kjms.2017.11.006","volume":"34","author":"TS Aydin","year":"2018","unstructured":"Aydin, T. S. et al. Optical coherence tomography findings in Parkinson\u2019s disease. Kaohsiung J. Med. Sci. 34, 166\u2013171 (2018).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"618_CR186","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1097\/IJG.0000000000000239","volume":"25","author":"M Eraslan","year":"2016","unstructured":"Eraslan, M. et al. Comparison of optical coherence tomography findings in patients with primary open-angle glaucoma and Parkinson disease. J. Glaucoma 25, e639\u2013e646 (2016).","journal-title":"J. Glaucoma"},{"key":"618_CR187","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mds.25747","volume":"29","author":"B Jimenez","year":"2014","unstructured":"Jimenez, B., Ascaso, F. J., Cristobal, J. A. & Lopez del Val, J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov. Disord. 29, 68\u201374 (2014).","journal-title":"Mov. Disord."},{"key":"618_CR188","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/WNO.0000000000000240","volume":"35","author":"M Kaur","year":"2015","unstructured":"Kaur, M. et al. Correlation between structural and functional retinal changes in Parkinson disease. J. Neuroophthalmol. 35, 254\u2013258 (2015).","journal-title":"J. Neuroophthalmol."},{"key":"618_CR189","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/08820538.2017.1307423","volume":"33","author":"MM Moschos","year":"2018","unstructured":"Moschos, M. M. & Chatziralli, I. P. Evaluation of choroidal and retinal thickness changes in Parkinson\u2019s disease using spectral domain optical coherence tomography. Semin. Ophthalmol. 33, 494\u2013497 (2018).","journal-title":"Semin. Ophthalmol."},{"key":"618_CR190","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1167\/iovs.16-20020","volume":"57","author":"A Pilat","year":"2016","unstructured":"Pilat, A. et al. In vivo morphology of the optic nerve and retina in patients with Parkinson\u2019s disease. Invest. Ophthalmol. Vis. Sci. 57, 4420\u20134427 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"618_CR191","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/eye.2013.4","volume":"27","author":"M Satue","year":"2013","unstructured":"Satue, M. et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson\u2019s disease patients. Eye 27, 507\u2013514 (2013).","journal-title":"Eye"},{"key":"618_CR192","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/bjophthalmol-2013-304152","volume":"98","author":"M Satue","year":"2014","unstructured":"Satue, M. et al. Retinal thinning and correlation with functional disability in patients with Parkinson\u2019s disease. Br. J. Ophthalmol. 98, 350\u2013355 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"618_CR193","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/aian.AIAN_152_18","volume":"21","author":"P Sengupta","year":"2018","unstructured":"Sengupta, P. et al. Optical coherence tomography findings in patients of Parkinson\u2019s disease: an Indian perspective. Ann. Indian Acad. Neurol. 21, 150\u2013155 (2018).","journal-title":"Ann. Indian Acad. Neurol."},{"key":"618_CR194","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/WNO.0b013e3182701745","volume":"33","author":"S Kirbas","year":"2013","unstructured":"Kirbas, S., Turkyilmaz, K., Tufekci, A. & Durmus, M. Retinal nerve fiber layer thickness in Parkinson disease. J. Neuroophthalmol. 33, 62\u201365 (2013).","journal-title":"J. Neuroophthalmol."},{"key":"618_CR195","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1468-1331.2012.03701.x","volume":"20","author":"C La Morgia","year":"2013","unstructured":"La Morgia, C. et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur. J. Neurol. 20, 198\u2013201 (2013).","journal-title":"Eur. J. Neurol."},{"key":"618_CR196","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-121975","volume":"34","author":"T Moreno-Ramos","year":"2013","unstructured":"Moreno-Ramos, T., Benito-Leon, J., Villarejo, A. & Bermejo-Pareja, F. Retinal nerve fiber layer thinning in dementia associated with Parkinson\u2019s disease, dementia with Lewy bodies, and Alzheimer\u2019s disease. J. Alzheimers Dis. 34, 659\u2013664 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"618_CR197","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2016.07.004","volume":"31","author":"T Ucak","year":"2016","unstructured":"Ucak, T. et al. Analysis of the retinal nerve fiber and ganglion cell\u2013inner plexiform layer by optical coherence tomography in Parkinson\u2019s patients. Parkinsonism Relat. Disord. 31, 59\u201364 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR198","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10072-012-1125-7","volume":"34","author":"M Rohani","year":"2013","unstructured":"Rohani, M. et al. Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson\u2019s disease. Neurol. Sci. 34, 689\u2013693 (2013).","journal-title":"Neurol. Sci."},{"key":"618_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48388-7","volume":"9","author":"MS Sung","year":"2019","unstructured":"Sung, M. S. et al. Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson\u2019s disease. Sci. Rep. 9, 11832 (2019).","journal-title":"Sci. Rep."},{"key":"618_CR200","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ophtha.2012.05.003","volume":"119","author":"E Garcia-Martin","year":"2012","unstructured":"Garcia-Martin, E. et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson\u2019s disease. Ophthalmology 119, 2161\u20132167 (2012).","journal-title":"Ophthalmology"},{"key":"618_CR201","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/mds.25896","volume":"29","author":"NM Roth","year":"2014","unstructured":"Roth, N. M. et al. Photoreceptor layer thinning in idiopathic Parkinson\u2019s disease. Mov. Disord. 29, 1163\u20131170 (2014).","journal-title":"Mov. Disord."},{"key":"618_CR202","first-page":"1427","volume":"4","author":"GD Aaker","year":"2010","unstructured":"Aaker, G. D. et al. Detection of retinal changes in Parkinson\u2019s disease with spectral-domain optical coherence tomography. Clin. Ophthalmol. 4, 1427\u20131432 (2010).","journal-title":"Clin. Ophthalmol."},{"key":"618_CR203","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034891","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht, P. et al. Optical coherence tomography in parkinsonian syndromes. PLoS ONE 7, e34891 (2012).","journal-title":"PLoS ONE"},{"key":"618_CR204","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.parkreldis.2011.03.004","volume":"17","author":"NK Archibald","year":"2011","unstructured":"Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Retinal thickness in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 17, 431\u2013436 (2011).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR205","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1111\/aos.12757","volume":"93","author":"D Bittersohl","year":"2015","unstructured":"Bittersohl, D. et al. Detection of retinal changes in idiopathic Parkinson\u2019s disease using high-resolution optical coherence tomography and Heidelberg retina tomography. Acta Ophthalmol. 93, e578\u2013e584 (2015).","journal-title":"Acta Ophthalmol."},{"key":"618_CR206","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2015.05.007","volume":"355","author":"J Chorostecki","year":"2015","unstructured":"Chorostecki, J. et al. Characterization of retinal architecture in Parkinson\u2019s disease. J. Neurol. Sci. 355, 44\u201348 (2015).","journal-title":"J. Neurol. Sci."},{"key":"618_CR207","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.parkreldis.2015.08.002","volume":"21","author":"P Mailankody","year":"2015","unstructured":"Mailankody, P. et al. Optical coherence tomography as a tool to evaluate retinal changes in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 1164\u20131169 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR208","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10633-015-9503-0","volume":"131","author":"B Nowacka","year":"2015","unstructured":"Nowacka, B., Lubinski, W., Honczarenko, K., Potemkowski, A. & Safranow, K. Bioelectrical function and structural assessment of the retina in patients with early stages of Parkinson\u2019s disease (PD). Doc. Ophthalmol. 131, 95\u2013104 (2015).","journal-title":"Doc. Ophthalmol."},{"key":"618_CR209","doi-asserted-by":"publisher","first-page":"238","DOI":"10.5935\/0004-2749.20140061","volume":"77","author":"LB Quagliato","year":"2014","unstructured":"Quagliato, L. B., Domingues, C., Quagliato, E. M., Abreu, E. B. & Kara-Junior, N. Applications of visual evoked potentials and Fourier-domain optical coherence tomography in Parkinson\u2019s disease: a controlled study. Arq. Bras. Oftalmol. 77, 238\u2013242 (2014).","journal-title":"Arq. Bras. Oftalmol."},{"key":"618_CR210","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s13760-019-01228-x","volume":"120","author":"B Tugcu","year":"2020","unstructured":"Tugcu, B. et al. Evaluation of retinal alterations in Parkinson disease and tremor diseases. Acta Neurol. Belg. 120, 107\u2013113 (2020).","journal-title":"Acta Neurol. Belg."},{"key":"618_CR211","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s11325-016-1366-4","volume":"20","author":"ZJ Yang","year":"2016","unstructured":"Yang, Z. J. et al. Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson\u2019s disease. Sleep. Breath. 20, 1285\u20131292 (2016).","journal-title":"Sleep. Breath."},{"key":"618_CR212","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3109\/02713683.2014.894080","volume":"39","author":"HA Bayhan","year":"2014","unstructured":"Bayhan, H. A., Aslan Bayhan, S., Tanik, N. & Gurdal, C. The association of spectral-domain optical coherence tomography determined ganglion cell complex parameters and disease severity in Parkinson\u2019s disease. Curr. Eye Res. 39, 1117\u20131122 (2014).","journal-title":"Curr. Eye Res."},{"key":"618_CR213","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ajo.2013.09.028","volume":"157","author":"E Garcia-Martin","year":"2014","unstructured":"Garcia-Martin, E. et al. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am. J. Ophthalmol. 157, 470\u2013478.e2 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"618_CR214","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/archophthalmol.2009.106","volume":"127","author":"ME Hajee","year":"2009","unstructured":"Hajee, M. E. et al. Inner retinal layer thinning in Parkinson disease. Arch. Ophthalmol. 127, 737\u2013741 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"618_CR215","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10072-018-3244-2","volume":"39","author":"M Unlu","year":"2018","unstructured":"Unlu, M., Gulmez Sevim, D., Gultekin, M. & Karaca, C. Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson\u2019s disease. Neurol. Sci. 39, 533\u2013541 (2018).","journal-title":"Neurol. Sci."},{"key":"618_CR216","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5114\/fn.2017.68584","volume":"55","author":"M Zivkovic","year":"2017","unstructured":"Zivkovic, M. et al. Retinal ganglion cell\/inner plexiform layer thickness in patients with Parkinson\u2019s disease. Folia Neuropathol. 55, 168\u2013173 (2017).","journal-title":"Folia Neuropathol."},{"key":"618_CR217","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2019.04.023","volume":"64","author":"A Chrysou","year":"2019","unstructured":"Chrysou, A., Jansonius, N. M. & van Laar, T. Retinal layers in Parkinson\u2019s disease: a meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat. Disord. 64, 40\u201349 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR218","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77833-1","volume":"10","author":"F Visser","year":"2020","unstructured":"Visser, F. et al. Visual hallucinations in Parkinson\u2019s disease are associated with thinning of the inner retina. Sci. Rep. 10, 21110 (2020).","journal-title":"Sci. Rep."},{"key":"618_CR219","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/WNO.0000000000000203","volume":"35","author":"ES Sari","year":"2015","unstructured":"Sari, E. S., Koc, R., Yazici, A., Sahin, G. & Ermis, S. S. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J. Neuroophthalmol. 35, 117\u2013121 (2015).","journal-title":"J. Neuroophthalmol."},{"key":"618_CR220","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00702-013-1093-y","volume":"121","author":"E Cubo","year":"2014","unstructured":"Cubo, E. et al. Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson\u2019s disease. J. Neural Transm. 121, 139\u2013145 (2014).","journal-title":"J. Neural Transm."},{"key":"618_CR221","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2018.06.016","volume":"56","author":"J Matlach","year":"2018","unstructured":"Matlach, J. et al. Retinal changes in Parkinson\u2019s disease and glaucoma. Parkinsonism Relat. Disord. 56, 41\u201346 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR222","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00702-013-1072-3","volume":"121","author":"M Schneider","year":"2014","unstructured":"Schneider, M. et al. Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. J. Neural Transm. 121, 41\u201347 (2014).","journal-title":"J. Neural Transm."},{"issue":"Suppl. 1","key":"618_CR223","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.parkreldis.2015.09.015","volume":"22","author":"S Miri","year":"2016","unstructured":"Miri, S., Glazman, S., Mylin, L. & Bodis-Wollner, I. A combination of retinal morphology and visual electrophysiology testing increases diagnostic yield in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22 (Suppl. 1), S134\u2013S137 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR224","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.parkreldis.2020.11.025","volume":"82","author":"JR Zhang","year":"2021","unstructured":"Zhang, J. R. et al. Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson\u2019s disease: a longitudinal study. Parkinsonism Relat. Disord. 82, 92\u201397 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"618_CR225","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1017\/S0952523800009779","volume":"7","author":"C Savy","year":"1991","unstructured":"Savy, C., Simon, A. & Nguyen-Legros, J. Spatial geometry of the dopamine innervation in the avascular area of the human fovea. Vis. Neurosci. 7, 487\u2013498 (1991).","journal-title":"Vis. Neurosci."},{"key":"618_CR226","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1016\/S0042-6989(97)00129-6","volume":"37","author":"MB Djamgoz","year":"1997","unstructured":"Djamgoz, M. B., Hankins, M. W., Hirano, J. & Archer, S. N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vis. Res. 37, 3509\u20133529 (1997).","journal-title":"Vis. Res."},{"key":"618_CR227","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0006-8993(94)91051-0","volume":"649","author":"I Nir","year":"1994","unstructured":"Nir, I. & Iuvone, P. M. Alterations in light-evoked dopamine metabolism in dystrophic retinas of mutant rds mice. Brain Res. 649, 85\u201394 (1994).","journal-title":"Brain Res."},{"key":"618_CR228","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/acn3.146","volume":"2","author":"S Miri","year":"2015","unstructured":"Miri, S. et al. The avascular zone and neuronal remodeling of the fovea in Parkinson disease. Ann. Clin. Transl. Neurol. 2, 196\u2013201 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"618_CR229","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cne.903000103","volume":"300","author":"CA Curcio","year":"1990","unstructured":"Curcio, C. A. & Allen, K. A. Topography of ganglion cells in human retina. J. Comp. Neurol. 300, 5\u201325 (1990).","journal-title":"J. Comp. Neurol."},{"key":"618_CR230","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ana.25972","volume":"89","author":"JY Lee","year":"2021","unstructured":"Lee, J. Y., Ahn, J., Shin, J. Y. & Jeon, B. Parafoveal change and dopamine loss in the retina with Parkinson\u2019s disease. Ann. Neurol. 89, 421\u2013422 (2021).","journal-title":"Ann. Neurol."},{"key":"618_CR231","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(99)00641-8","volume":"353","author":"BA Faucheux","year":"1999","unstructured":"Faucheux, B. A., Bonnet, A. M., Agid, Y. & Hirsch, E. C. Blood vessels change in the mesencephalon of patients with Parkinson\u2019s disease. Lancet 353, 981\u2013982 (1999).","journal-title":"Lancet"},{"key":"618_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68488-z","volume":"10","author":"N Froger","year":"2020","unstructured":"Froger, N. et al. VEGF is an autocrine\/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci. Rep. 10, 12409 (2020).","journal-title":"Sci. Rep."},{"key":"618_CR233","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00702-011-0684-8","volume":"119","author":"B Desai Bradaric","year":"2012","unstructured":"Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M. & Hendey, B. Evidence for angiogenesis in Parkinson\u2019s disease, incidental Lewy body disease, and progressive supranuclear palsy. J. Neural Transm. 119, 59\u201371 (2012).","journal-title":"J. Neural Transm."},{"key":"618_CR234","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/01.wnr.0000215769.71657.65","volume":"17","author":"K Wada","year":"2006","unstructured":"Wada, K. et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson\u2019s disease. Neuroreport 17, 705\u2013709 (2006).","journal-title":"Neuroreport"},{"key":"618_CR235","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.expneurol.2007.05.012","volume":"206","author":"T Yasuda","year":"2007","unstructured":"Yasuda, T. et al. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson\u2019s disease. Exp. Neurol. 206, 308\u2013317 (2007).","journal-title":"Exp. Neurol."},{"key":"618_CR236","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mds.26533","volume":"31","author":"JY Lee","year":"2016","unstructured":"Lee, J. Y. et al. Lateral geniculate atrophy in Parkinson\u2019s with visual hallucination: a trans-synaptic degeneration? Mov. Disord. 31, 547\u2013554 (2016).","journal-title":"Mov. Disord."},{"key":"618_CR237","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/brain\/awaa461","volume":"144","author":"NP Oxtoby","year":"2021","unstructured":"Oxtoby, N. P. et al. Sequence of clinical and neurodegeneration events in Parkinson\u2019s disease progression. Brain 144, 975\u2013988 (2021).","journal-title":"Brain"},{"key":"618_CR238","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/brain\/awm111","volume":"130","author":"CH Williams-Gray","year":"2007","unstructured":"Williams-Gray, C. H., Foltynie, T., Brayne, C. E., Robbins, T. W. & Barker, R. A. Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort. Brain 130, 1787\u20131798 (2007).","journal-title":"Brain"},{"key":"618_CR239","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/mds.28477","volume":"36","author":"A Zarkali","year":"2021","unstructured":"Zarkali, A., McColgan, P., Leyland, L. A., Lees, A. J. & Weil, R. S. Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson\u2019s disease. Mov. Disord. 36, 1191\u20131202 (2021).","journal-title":"Mov. Disord."},{"key":"618_CR240","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/CPJ.0000000000000719","volume":"10","author":"LA Leyland","year":"2020","unstructured":"Leyland, L. A. et al. Visual tests predict dementia risk in Parkinson disease. Neurol. Clin. Pract. 10, 29\u201339 (2020).","journal-title":"Neurol. Clin. Pract."},{"key":"618_CR241","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10072-020-04289-6","volume":"41","author":"SB Hong","year":"2020","unstructured":"Hong, S. B. et al. Contrast sensitivity impairment in drug-naive Parkinson\u2019s disease patients associates with early cognitive decline. Neurol. Sci. 41, 1837\u20131842 (2020).","journal-title":"Neurol. Sci."},{"key":"618_CR242","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41433-020-01286-z","volume":"35","author":"E Akyol","year":"2021","unstructured":"Akyol, E., Hagag, A. M., Sivaprasad, S. & Lotery, A. J. Adaptive optics: principles and applications in ophthalmology. Eye 35, 244\u2013264 (2021).","journal-title":"Eye"},{"key":"618_CR243","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.preteyeres.2016.11.001","volume":"57","author":"ZM Dong","year":"2017","unstructured":"Dong, Z. M., Wollstein, G., Wang, B. & Schuman, J. S. Adaptive optics optical coherence tomography in glaucoma. Prog. Retin. Eye Res. 57, 76\u201388 (2017).","journal-title":"Prog. Retin. Eye Res."},{"key":"618_CR244","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaophthalmol.2020.5730","volume":"139","author":"CB Robbins","year":"2021","unstructured":"Robbins, C. B. et al. Characterization of retinal microvascular and choroidal structural changes in Parkinson disease. JAMA Ophthalmol. 139, 182\u2013188 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"618_CR245","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.21037\/qims-20-460","volume":"10","author":"J Zou","year":"2020","unstructured":"Zou, J. et al. Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson\u2019s disease. Quant. Imaging Med. Surg. 10, 1930\u20131939 (2020).","journal-title":"Quant. Imaging Med. Surg."},{"key":"618_CR246","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93621","volume":"2","author":"Y Koronyo","year":"2017","unstructured":"Koronyo, Y. et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight 2, e93621 (2017).","journal-title":"JCI Insight"},{"key":"618_CR247","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/cells7060060","volume":"7","author":"TE Yap","year":"2018","unstructured":"Yap, T. E., Donna, P., Almonte, M. T. & Cordeiro, M. F. Real-time imaging of retinal ganglion cell apoptosis. Cells 7, 60 (2018).","journal-title":"Cells"},{"key":"618_CR248","doi-asserted-by":"publisher","first-page":"13352","DOI":"10.1073\/pnas.0405479101","volume":"101","author":"MF Cordeiro","year":"2004","unstructured":"Cordeiro, M. F. et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl Acad. Sci. USA 101, 13352\u201313356 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"618_CR249","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/brain\/awx088","volume":"140","author":"MF Cordeiro","year":"2017","unstructured":"Cordeiro, M. F. et al. Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. Brain 140, 1757\u20131767 (2017).","journal-title":"Brain"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00618-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:45:13Z","timestamp":1700225113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":249,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00618-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"13 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}